Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
about
Newer therapies for the treatment of metastatic breast cancer: a clinical updateBeyond taxanes: the next generation of microtubule-targeting agentsEpidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestrySystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesIxabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialSystematic review of ixabepilone for treating metastatic breast cancer.A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials.A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trialsPhase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patientsIxabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.Overall survival as the outcome for randomized clinical trials with effective subsequent therapiesSynergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.Phase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patientsEribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.Eribulin mesylate in the treatment of metastatic breast cancerPhase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxaneRandomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCAdvances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).Current approaches to the management of Her2-negative metastatic breast cancer.Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsHealth-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trialTITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cellsUpdate on taxane development: new analogs and new formulationsChemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane TreatmentWhich patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint.Optimal management of bone metastases in breast cancer patients.Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.
P2860
Q26865260-0C0174A1-8BCB-4BC7-B90C-6D027977C5BEQ26865369-8D761464-8DE6-46C5-8F18-6198935AF29EQ27011535-1E620F86-C7F1-49D9-B912-7C22D145FA23Q28080469-A6CD3390-AEF7-4565-881A-A56A69950C94Q28534786-D42C08CE-6F36-4CBE-A7C0-39CCD1767860Q30248627-67F6D3B5-E719-41BD-834C-635FAF3CE55FQ30390845-41015F91-E5D5-49D1-8EA1-1AC7D0DC83BAQ33430813-5D324B4C-9EFF-45F6-9FE8-390FD42399A7Q33762423-3C754D90-086B-492C-A6D0-9871843B8EB5Q33769821-C816FCE7-7BED-4812-BCED-77DF391A397FQ34180965-B2B16159-8C80-4A41-845E-08F3E252165CQ34307937-CEFE1FC1-1D90-447B-AF07-071B1AFDA783Q34458907-616C921E-0599-4176-9FEF-D48631123A37Q34562783-0B7D9016-37F9-465C-873B-39B08B2607E8Q34788890-1B034514-CB61-4133-AF60-1FD2B36804E9Q35023481-CBF3B723-FEFE-435A-82DF-B438A281CE6BQ35076330-429E74CF-74EB-4E04-B8CC-511C71BFF7ADQ35482173-30BABEA3-6DD8-45DA-94D6-6B3F2754DFC4Q35599745-C7C54D9F-533B-4FB4-B180-2DB28DC2A619Q35699382-3AD98F8E-5069-42D2-97D3-BD55F8F978CCQ35721526-2D96E463-DE75-422C-82A1-1C3EA15739CCQ35847455-7A949EE8-B853-4D70-9745-2F149D731C88Q35872691-68ACB422-71F3-42BB-9CEA-B43AFE61933AQ35975007-F1B7A86B-F6EF-4624-87B7-BCB56EEA1552Q36132957-F5E87B21-FEC7-4450-B8AA-59F232452CB0Q36245461-1C815526-0325-4268-B35F-495B76FDA1F9Q36273796-79EE3B8A-CAD0-41F6-B0E3-E33F80C5C6EEQ36322815-FD906D18-C6CD-4C41-8355-BA6610FCBD4CQ36372761-62934F96-9558-4245-B136-945F91808C9CQ36457669-BBFD05C1-557C-4A90-A0F8-042A6FC8EA45Q36470377-F39A6545-E43D-41B6-81E4-25C62010BFC6Q36630732-986C57DF-FDBD-4914-8E05-8450F1CEF5BBQ36636872-520F891A-A8FF-41D5-822D-8122573D3EFAQ36892821-5E517D7B-ADC8-494F-AAF3-400D347E226AQ37169723-E42AB35D-3873-40C6-9094-94BA3304F81CQ37176391-8CDC931E-23A7-40FF-9748-A01098CD9457Q37236305-2F7FF12B-1FA0-4A3D-989F-09146D340D93Q37292020-3B970220-6630-4FB4-9892-3FAF89439BB5Q37355487-6EF69779-153C-4C63-BFD9-FDC7417C5C94Q37398150-93D55ABE-443F-4379-A839-1B2904D6A0B7
P2860
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Randomized phase III trial of ...... an anthracycline and a taxane
@ast
Randomized phase III trial of ...... an anthracycline and a taxane
@en
type
label
Randomized phase III trial of ...... an anthracycline and a taxane
@ast
Randomized phase III trial of ...... an anthracycline and a taxane
@en
prefLabel
Randomized phase III trial of ...... an anthracycline and a taxane
@ast
Randomized phase III trial of ...... an anthracycline and a taxane
@en
P2093
P2860
P356
P1476
Randomized phase III trial of ...... an anthracycline and a taxane
@en
P2093
Alexey Manikhas
Carlos Medina
Eduard Vrdoljak
Gonzalo Rubio
Gumersindo Perez Manga
Joseph A Sparano
Jungsil Ro
Monica Rondinon
Oliver Rixe
P2860
P304
P356
10.1200/JCO.2009.24.4244
P407
P577
2010-06-07T00:00:00Z